Biomarker-Guided Diagnosis in Critical Illness

Abstract

Biomarker-guided diagnosis is transforming the field of critical care by enabling earlier detection, improved risk stratification, and more precise therapeutic interventions in critically ill patients. This review explores the current landscape of biomarkers in critical illness, with a focus on sepsis, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction. Emphasis is placed on recent evidence, mechanistic insights, and the integration of biomarker data into clinical decision-making. The review further discusses the practical implications of biomarker-guided approaches, recent advances, emerging therapies, and relevant guideline recommendations, aiming to provide clinicians with an up-to-date synthesis to inform optimal patient care in the intensive care setting.

Introduction

The management of critical illness presents unique challenges due to heterogeneity in underlying etiologies, rapidly evolving pathophysiology, and the need for timely, accurate diagnosis. Traditional diagnostic criteria based on clinical assessment and standard laboratory parameters often lack sensitivity and specificity, resulting in diagnostic uncertainty and delayed interventions. In recent years, the integration of biomarkers measurable biological indicators reflecting pathophysiological processes has emerged as a promising strategy to enhance diagnostic precision, guide management, and improve outcomes in the critically ill. This article reviews the evolving role of biomarker-guided diagnosis in critical illness, with an emphasis on recent advances and clinical application for healthcare professionals.

Epidemiology / Disease Burden

Critical illnesses, including sepsis, ARDS, and multi-organ dysfunction syndrome (MODS), account for significant morbidity and mortality worldwide. Sepsis alone affects over 49 million individuals annually and leads to approximately 11 million deaths. ARDS and MODS further contribute to prolonged intensive care unit (ICU) stays and increased healthcare costs. Diagnostic delays and misclassification are common, compounding the disease burden by impeding timely therapeutic intervention. The utilisation of biomarkers has the potential to mitigate this burden by facilitating early and accurate diagnosis, thereby improving resource utilisation and patient outcomes.

Pathophysiology

Critical illness involves complex, dynamic interactions between host response and underlying disease triggers. In sepsis, for example, the dysregulated host response to infection results in systemic inflammation, endothelial dysfunction, and coagulation abnormalities. ARDS is characterised by diffuse alveolar damage and increased vascular permeability, leading to hypoxemia and respiratory failure. Biomarkers reflect specific aspects of these pathophysiological processes: procalcitonin (PCT) and C-reactive protein (CRP) signal systemic inflammation; interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) indicate cytokine activation; and troponins or brain natriuretic peptide (BNP) denote cardiac involvement. Understanding these mechanistic relationships is essential for interpreting biomarker measurements in the clinical context.

Risk Factors

Risk factors for critical illness are multifactorial and include advanced age, chronic comorbidities (such as diabetes, chronic kidney disease, and immunosuppression), recent surgery or trauma, and exposure to hospital-acquired infections. Certain biomarkers can help identify patients at increased risk of deterioration or progression to multi-organ failure. For instance, elevated lactate levels are associated with tissue hypoperfusion and worse prognosis in sepsis, while high soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) levels may predict the development of sepsis in high-risk populations. Recognising these risk factors and corresponding biomarker responses facilitates early intervention and tailored monitoring strategies.

Clinical Features

Clinical presentation of critical illness is often non-specific and may include fever or hypothermia, tachycardia, hypotension, altered mental status, and respiratory distress. Distinguishing between infectious and non-infectious etiologies, or between systemic inflammation and organ dysfunction, is challenging based solely on clinical features. Biomarker-guided assessment can augment the diagnostic process: elevated PCT suggests bacterial infection, while increased CRP reflects inflammation but lacks specificity for etiology. Additional biomarkers, such as presepsin and mid-regional pro-adrenomedullin (MR-proADM), offer further discriminatory value in complex clinical scenarios.

Diagnosis

Biomarker-guided diagnosis involves the integration of laboratory measurements with clinical assessment to increase diagnostic confidence and reduce uncertainty. In sepsis, the combination of PCT, CRP, and IL-6 improves diagnostic accuracy over clinical criteria alone. In ARDS, protein biomarkers such as surfactant protein D (SP-D) and receptor for advanced glycation end-products (RAGE) may help distinguish ARDS from cardiogenic pulmonary edema. Serial biomarker measurements can also inform disease trajectory and response to therapy. Point-of-care testing for selected biomarkers has further streamlined diagnostic workflows, enabling rapid bedside decision-making in the ICU.

Treatment & Management

Biomarker measurements play a pivotal role in guiding treatment decisions in critical care. Procalcitonin-guided antibiotic stewardship protocols have demonstrated reductions in antibiotic exposure and associated adverse events without compromising clinical outcomes. Lactate clearance is used to guide resuscitation in septic shock. Biomarkers of cardiac stress (BNP, troponin) inform fluid management and vasopressor selection in patients with combined septic and cardiogenic shock. Individualisation of therapy based on biomarker trends represents a paradigm shift towards precision medicine in critical care, optimising resource utilisation and minimising harm.

Recent Advances / Emerging Therapies

Recent years have witnessed the discovery of novel biomarkers with potential to further refine diagnosis and prognosis in critical illness. Genomic, transcriptomic, and proteomic technologies are enabling the identification of biomarker panels that reflect multiple pathogenic pathways. For example, multi-marker models such as the Sepsis MetaScore integrate transcriptomic data to improve sepsis diagnosis. Machine learning algorithms are being developed to interpret complex biomarker data and provide real-time risk stratification. Ongoing trials are evaluating the utility of emerging biomarkers such as angiopoietins, microRNAs, and cell-free DNA in various critical illness syndromes. These advances promise to enhance the precision and timeliness of critical care diagnostics.

Guideline Recommendations

Major critical care guidelines increasingly recognise the value of biomarkers in diagnosis and management. The Surviving Sepsis Campaign recommends the use of PCT to support the diagnosis of sepsis and guide antimicrobial therapy, with serial measurements to monitor clinical course. The American Thoracic Society suggests consideration of protein biomarkers in the diagnosis of ARDS, though clinical utility is still evolving. Guidelines emphasise the need to interpret biomarkers within the broader clinical context, avoiding over-reliance on single measurements and acknowledging assay limitations. Multidisciplinary collaboration and ongoing education are essential to optimise biomarker use in routine practice.

Conclusion

Biomarker-guided diagnosis represents a major advancement in the management of critical illness, offering the potential for earlier detection, improved risk assessment, and more individualised treatment strategies. While challenges remain in standardisation, interpretation, and integration with clinical workflows, recent advances are paving the way for precision diagnostics in the ICU. Continued research, technological innovation, and adherence to evidence-based guidelines will be essential to fully realise the benefits of biomarker-guided approaches and improve outcomes for critically ill patients.